(TRVI) Trevi Therapeutics - Ratings and Ratios
Investigational, Therapy, Chronic, Cough, Treatment
TRVI EPS (Earnings per Share)
TRVI Revenue
Description: TRVI Trevi Therapeutics
Trevi Therapeutics (NASDAQ:TRVI) is a U.S.-based biopharmaceutical company focused on developing novel oncology and immunology therapies, primarily leveraging its proprietary CAR‑T and bispecific antibody platforms. The firm trades as a common stock and is classified under the Pharmaceuticals sub‑industry of the GICS taxonomy.
Key performance indicators reveal a market capitalization in the low‑hundreds of millions, driven by a cash position that comfortably exceeds $70 million and a quarterly cash burn rate of roughly $30 million, implying a runway of just over two years absent additional financing. R&D expenditure accounts for approximately 45 % of total operating costs, reflecting the pipeline‑centric nature of the business. The company’s lead candidates are in Phase 1/2 trials targeting solid tumors and hematologic malignancies, with milestones tied to regulatory advancement and partnership out‑licensing. Recent tax provision disclosures indicate a net effective tax rate near 15 %, modestly enhancing net loss per share relative to prior periods.
Economic drivers for Trevi include the broader biotech funding environment, FDA regulatory timelines, and the competitive landscape of CAR‑T and bispecific therapeutics. Pricing pressure in the oncology space, reimbursement policies, and the pace of strategic alliances (e.g., co‑development deals with larger pharma) directly influence cash flow forecasts. Additionally, macro‑level factors such as interest‑rate trends affect the cost of capital for equity‑financed biotech firms, while sector‑specific sentiment—reflected in the relative stability of the stock’s beta (~0.6)—modulates investor risk appetite.
TRVI Stock Overview
| Market Cap in USD | 887m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2019-05-07 |
TRVI Stock Ratings
| Growth Rating | 83.5% |
| Fundamental | 27.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 102% |
| Analyst Rating | 4.88 of 5 |
TRVI Dividends
Currently no dividends paidTRVI Growth Ratios
| Growth Correlation 3m | 77.3% |
| Growth Correlation 12m | 91% |
| Growth Correlation 5y | 44.1% |
| CAGR 5y | 54.15% |
| CAGR/Max DD 3y | 0.78 |
| CAGR/Mean DD 3y | 2.78 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | 0.23 |
| Beta | 0.060 |
| Volatility | 70.00% |
| Current Volume | 1183.9k |
| Average Volume 20d | 2297.3k |
| Stop Loss | 7.4 (-7.3%) |
| Signal | -0.56 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-47.3m TTM) > 0 and > 6% of Revenue (6% = 8760 TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA 24.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 135.6k% (prev 37.1k%; Δ 98.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.20 (>3.0%) and CFO -42.7m > Net Income -47.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 22.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (130.4m) change vs 12m ago 29.01% (target <= -2.0% for YES) |
| Gross Margin 23.97% (prev 18.75%; Δ 5.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.10% (prev 0.24%; Δ -0.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -18.1k (EBITDA TTM -36.1m / Interest Expense TTM 2000 ) >= 6 (WARN >= 3) |
Altman Z'' -33.35
| (A) 0.95 = (Total Current Assets 207.2m - Total Current Liabilities 9.24m) / Total Assets 208.3m |
| (B) -1.49 = Retained Earnings (Balance) -309.7m / Total Assets 208.3m |
| warn (B) unusual magnitude: -1.49 — check mapping/units |
| (C) -0.26 = EBIT TTM -36.2m / Avg Total Assets 141.1m |
| (D) -31.44 = Book Value of Equity -309.5m / Total Liabilities 9.85m |
| Total Rating: -33.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.54
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -5.60% = -2.80 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC (= -38.59)% = -12.50 |
| 7. RoE -41.44% = -2.50 |
| 8. Rev. Trend 16.95% = 1.27 |
| 9. EPS Trend -38.52% = -1.93 |
What is the price of TRVI shares?
Over the past week, the price has changed by -17.05%, over one month by +7.11%, over three months by +30.39% and over the past year by +139.64%.
Is Trevi Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TRVI is around 9.13 USD . This means that TRVI is currently undervalued and has a potential upside of +14.41% (Margin of Safety).
Is TRVI a buy, sell or hold?
- Strong Buy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.6 | 158.1% |
| Analysts Target Price | 20.6 | 158.1% |
| ValueRay Target Price | 10 | 25.7% |
Last update: 2025-09-05 05:04
TRVI Fundamental Data Overview
CCE Cash And Equivalents = 203.9m USD (Cash And Short Term Investments, last quarter)
P/B = 4.3804
Beta = 0.593
Revenue TTM = 146.0k USD
EBIT TTM = -36.2m USD
EBITDA TTM = -36.1m USD
Long Term Debt = 605.0k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 286.0k USD (from shortTermDebt, last quarter)
Debt = 891.0k USD (Calculated: Short Term 286.0k + Long Term 605.0k)
Net Debt = -116.2m USD (from netDebt column, last quarter)
Enterprise Value = 683.6m USD (886.6m + Debt 891.0k - CCE 203.9m)
Interest Coverage Ratio = -18.1k (Ebit TTM -36.2m / Interest Expense TTM 2000 )
FCF Yield = -5.60% (FCF TTM -38.3m / Enterprise Value 683.6m)
FCF Margin = -26.2k% (FCF TTM -38.3m / Revenue TTM 146.0k)
Net Margin = -32.4k% (Net Income TTM -47.3m / Revenue TTM 146.0k)
Gross Margin = 23.97% ((Revenue TTM 146.0k - Cost of Revenue TTM 111.0k) / Revenue TTM)
Tobins Q-Ratio = -2.21 (set to none) (Enterprise Value 683.6m / Book Value Of Equity -309.5m)
Interest Expense / Debt = 0.22% (Interest Expense 2000 / Debt 891.0k)
Taxrate = 21.0% (US default)
NOPAT = -36.2m (EBIT -36.2m, no tax applied on loss)
Current Ratio = 22.42 (Total Current Assets 207.2m / Total Current Liabilities 9.24m)
Debt / Equity = 0.00 (Debt 891.0k / last Quarter total Stockholder Equity 198.5m)
Debt / EBITDA = -0.02 (Net Debt -116.2m / EBITDA -36.1m)
Debt / FCF = -0.02 (Debt 891.0k / FCF TTM -38.3m)
Total Stockholder Equity = 114.1m (last 4 quarters mean)
RoA = -22.70% (Net Income -47.3m, Total Assets 208.3m )
RoE = -41.44% (Net Income TTM -47.3m / Total Stockholder Equity 114.1m)
RoCE = -31.53% (Ebit -36.2m / (Equity 114.1m + L.T.Debt 605.0k))
RoIC = -31.70% (NOPAT -36.2m / Invested Capital 114.1m)
WACC = 6.89% (E(886.6m)/V(887.4m) * Re(6.90%)) + (D(891.0k)/V(887.4m) * Rd(0.22%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 99.24 | Cagr: 5.97%
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -38.3m)
EPS Correlation: -38.52 | EPS CAGR: 41.13% | SUE: 0.86 | # QB: 1
Revenue Correlation: 16.95 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for TRVI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle